1.            Yong MK, Thursky K, Crane M, Spelman T, Mahar RK, Simpson JA, et al. Interferon-alpha Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial. Clin Infect Dis. 2025.

2.            Williams LJ, Li-Wai-Suen CS, Garnham AL, Bader SM, Tam CS, Whitechurch A, et al. Elucidating novel immune profiles for predicting infection in high-risk cohorts: a pilot study in patients with relapsed and refractory chronic lymphocytic leukaemia. Clin Transl Immunology. 2025;14(8):e70049.

3.            Westall GP, Gottlieb D, Hughes P, Marinelli T, Rawlinson WD, Ritchie D, et al. Emerging concepts of CMV in transplantation. Intern Med J. 2025;55(1):12-9.

4.            Wang X, Patel C, Giles ML, Burns P, Macartney K, Teh B, et al. Glucocorticoid Dosing and Implications for Vaccination: Evolution of Global Definitions. Clin Infect Dis. 2025;80(5):998-1004.

5.            Urbancic KF, Kong DCM, Johnson PDR, Yong MK, Slavin MA, Thursky K. Antifungal stewardship in Australian hospitals: defining the scope and future targets. Intern Med J. 2025;55(2):223-32.

6.            Thorburn S, Vogrin S, Garner S, Smibert O, Reynolds G, Kwong J, et al. Predictors of early line removal and successful line retention in potential central line-associated bloodstream infections in haematology patients: a retrospective cohort study. J Hosp Infect. 2025;162:284-92.

7.            Stewart AG, Laupland KB, Edwards F, Slavin MA, Chen SC. Epidemiology, Significance and Clinical Outcomes of Bloodstream Infections Caused by Non-Candida and Non-Cryptococcus Yeasts. Mycoses. 2025;68(7):e70093.

8.            Stewart AG, Laupland KB, Edwards F, Koo S, Hammond SP, Harris PN, et al. Population-based longitudinal study over two decades of Candida and Candida-like species bloodstream infection reveals gender and species differences in mortality, recurrence and resistance. J Infect. 2025;91(1):106513.

9.            Stewart AG, Laupland KB, Edwards F, Gassiep I, Koo S, Hammond SP, et al. Clinical Characteristics and Outcomes in Patients With Cryptococcaemia From a Large Population-Based Cohort. Mycoses. 2025;68(7):e70091.

10.         Smibert OC, Vogrin S, Sinclair M, Majumdar A, Nasra M, Pandey D, et al. Antibiotic Exposure and Risk of Allograft Rejection and Survival After Liver Transplant: An Observational Cohort Study From a Tertiary Referral Centre. Transpl Infect Dis. 2025;27(3):e70026.

11.         Roberts JA, Sime FB, Lipman J, Hernandez-Mitre MP, Baptista JP, Bruggemann RJ, et al. Are contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter pharmacokinetics study for Screening Antifungal Exposure in Intensive Care Units-the SAFE-ICU study. Intensive Care Med. 2025;51(2):302-17.

12.         Reynolds GK, Slavin MA. The bottom line of CAR-T fungal risk: low incidence, high stakes and the need for individualised antifungal prophylaxis. Transplant Cell Ther. 2025;31(1):4-6.

13.         Puerta-Alcalde P, O'Keefe J, Woolstencroft R, Kaul S, Lopez N, Cronin K, et al. Clostridioides difficile infection and recurrence in cancer patients (CIRCA): A multicentre, international study. Int J Infect Dis. 2025;153:107785.

14.         Ng I, James F, Copaescu A, Vogrin S, Mitri E, Rose M, et al. Prolonged versus single dose in penicillin oral challenge testing: protocols for a pilot and definitive randomised controlled trial (PROSPECTOR studies). BMJ Open. 2025;15(2):e094712.

15.         Marinelli T, Teh B, Giannella M, Ison MG, Roberts MB, Bupha-Intr O, et al. Current Practice Patterns and Educational Needs of Immunocompromised Infectious Diseases Physicians in Australia and New Zealand. Transpl Infect Dis. 2025;27(4):e70087.

16.         Maertens JA, Thompson GR, 3rd, Spec A, Donovan FM, Hammond SP, Bruns AHW, et al. Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study. Lancet Infect Dis. 2025.

17.         Liu AJ, Slavin MA, Harrison SJ, Teh BW. Infections during novel myeloma therapies. Leuk Lymphoma. 2025;66(3):420-32.

18.         Kinsella P, Thursky K, Slavin MA, Reynolds GK. From guesswork to guidelines: advancing diagnostic stewardship in immunocompromised hosts. Expert Rev Anti Infect Ther. 2025;23(9):723-37.

19.         Khawaja F, Zamora D, Yong MK, Hakki M, Goscicki BK, Danziger-Isakov L, et al. American Society for Transplantation and Cellular Therapy Series #11: Updated Cytomegalovirus Guidelines in Hematopoietic Cell Transplant and Cellular Therapy Recipients. Transplant Cell Ther. 2025.

20.         Khanina A, Singh N, James R, Kong DCM, Slavin MA, Thursky KA. Assessing the appropriateness of antifungal prescribing: key results from the implementation of a novel audit tool in Australian hospitals. J Antimicrob Chemother. 2025;80(4):1127-36.

21.         Hodges MR, Tawadrous M, Cornely OA, Thompson GR, 3rd, Slavin MA, Maertens JA, et al. Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS). Clin Infect Dis. 2025.

22.         Han W, Martinez D, Rozova V, Cavedon L, Khanina A, Worth LJ, et al. Automated Detection of Invasive Fungal Infections in Clinical Reports Using Medical Language Models. Stud Health Technol Inform. 2025;329:1002-7.

23.         Hall VG, Smibert OC, Sullivan SG, Lim C, Barr IG, Peck H, et al. Influenza Vaccination Strategies in Patients with Hematologic Cancer. N Engl J Med. 2025;392(3):306-8.

24.         Hall VG, Nguyen THO, Smibert OC, Allen LF, Sullivan SG, Fox A, et al. Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial. J Infect Dis. 2025.

25.         Haidar G, Thomas S, Loubet P, Baker RI, Benfield T, Boonyaratanakornkit J, et al. Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial. Lancet Infect Dis. 2025;25(7):813-26.

26.         Giannella M, Riccucci D, Pascale R, Cordero E, Mueller NJ, Slavin M, et al. Current Practice Patterns and Educational Needs of the ESCMID Study Group for Infections in Compromised Hots. Transpl Infect Dis. 2025;27(4):e70076.

27.         Giannella M, Lanternier F, Delliere S, Groll AH, Mueller NJ, Alastruey-Izquierdo A, et al. Invasive fungal disease in the immunocompromised host: changing epidemiology, new antifungal therapies, and management challenges. Clin Microbiol Infect. 2025;31(1):29-36.

28.         Garg P, Singh N, Liu AJ, Yong MK, Slavin MA, Hall L, et al. Estimating the prevalence of key healthcare-associated and opportunistic infections in Australian transplant and cancer populations: protocol for the PROSPER point prevalence study. BMJ Open. 2025;15(7):e100798.

29.         Douglas AP, Stohs E, Mikulska M. The role of antibacterial prophylaxis in high-risk neutropenia: benefits, risks, and current perspectives. Curr Opin Infect Dis. 2025;38(4):281-9.

30.         Coussement J, Heath CH, Roberts MB, Lane RJ, Spelman T, Smibert OC, et al. Management, Outcomes, and Predictors of Mortality of Cryptococcus Infection in Patients Without HIV: A Multicenter Study in 46 Hospitals in Australia and New Zealand. Clin Infect Dis. 2025;80(4):817-25.

31.         Chung H, Krishnasamy M, Joyce T, Dryden T, Whitechurch A, Baden P, et al. "It's a risk-benefit analysis": Qualitative perspectives on barriers and enablers to post-treatment vaccination from adults affected by a haematological malignancy in Australia. Vaccine. 2025;50:126826.

32.         Bartoletti M, Azap O, Barac A, Ben Selma M, Ergonul O, Gkrania-Klotsas E, et al. Management of COVID-19 in immunocompromised patients: an European Society of Clinical Microbiology and Infectious Diseases consensus document. Clin Microbiol Infect. 2025.